Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis C. Calabrese, A. Tosco, P. Abete, V. Carnovale,

Slides:

Advertisements

Similar presentations

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Advertisements

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

The prevalence of “risky behaviour” in adults with cystic fibrosis

Treatment compliance in children and adults with Cystic Fibrosis

William G. Flight, Jonathan Shaw, Susan Johnson, A

R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.

Single high-dose oral vitamin D3 (stoss) therapy — A solution to vitamin D deficiency in children with cystic fibrosis? Darren Shepherd, Yvonne Belessis,

Patrick A. Flume, John P. Clancy, George Z. Retsch-Bogart, D

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Cirrhosis and other liver disease in cystic fibrosis

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

John Widger, Sarath Ranganathan, Philip J. Robinson

Controlled clinical trials in cystic fibrosis — are we doing better?

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state Bradley.

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Cystic fibrosis mortality trend in Italy from 1970 to 2011

Claire Keating, Armeen D

Long-term daily high and low doses of azithromycin in children with cystic fibrosis: A randomized controlled trial S.K. Kabra, R. Pawaiya, Rakesh Lodha,

International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients Drucy Borowitz, Christopher Stevens,

Spontaneous coronary artery dissection associated with coughing

A.H. Gifford Journal of Cystic Fibrosis

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Tregony Simoneau, Gregory S. Sawicki, Carly E. Milliren, Henry A

Inhalation solutions — Which ones may be mixed

Physiologic endpoints for clinical studies for cystic fibrosis

Characterisation of mutations and genotype–phenotype correlation in cystic fibrosis: Experience from India Shivaram S. Shastri, Madhulika Kabra, Sushil.

Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis Christopher R. Sudfeld, Elliott C. Dasenbrook, William.

Elliott C. Dasenbrook, Gregory S. Sawicki Journal of Cystic Fibrosis

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint M.W. Konstan, J.S. Wagener, A. Yegin, S.J.

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis M.N. Hurley, A.H. Amin Ariff, C. Bertenshaw,

C. Van de Kerkhove, P. C. Goeminne, M. Kicinski, T. S. Nawrot, N

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

Voriconazole therapy in children with cystic fibrosis

V. Terlizzi, A. Tosco, R. Tomaiuolo, A. Sepe, N. Amato, A. Casale, C

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate.

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

CFTR modulators and pregnancy: Our work has only just begun

Beta-lactam allergy in adults with cystic fibrosis

Predictors of non-referral of patients with cystic fibrosisfor lung transplant evaluation in the United States Kathleen J. Ramos, Bradley S. Quon, Kevin.

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa C.E. Wainwright, A.L. Quittner, D.E.

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis D.J. Touw, A.J. Knox,

Cystic fibrosis and pregnancy in the modern era: A case control study

Presentation transcript:

Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis C. Calabrese, A. Tosco, P. Abete, V. Carnovale, C. Basile, A. Magliocca, S. Quattrucci, S. De Sanctis, F. Alatri, G. Mazzarella, L. De Pietro, C. Turino, E. Melillo, P. Buonpensiero, A. Di Pasqua, V. Raia Journal of Cystic Fibrosis Volume 14, Issue 2, Pages 203-210 (March 2015) DOI: 10.1016/j.jcf.2014.09.014 Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Study timeline. Journal of Cystic Fibrosis 2015 14, 203-210DOI: (10.1016/j.jcf.2014.09.014) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Flow diagram of study population. Journal of Cystic Fibrosis 2015 14, 203-210DOI: (10.1016/j.jcf.2014.09.014) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Changes from baseline of FEV1 at each study visit measured in children as liter with standard error (A) and percentage predicted with standard error (B); in adults as liter with standard error (C) and percentage predicted with standard error (D); in patients with FEV1% <81% as liter with standard error (E) and percentage predicted with standard error (F); in patients with FEV1% >81% as liter with standard error (G) and percentage predicted with standard error (H). Dark gray: glutathione; light gray: placebo. Journal of Cystic Fibrosis 2015 14, 203-210DOI: (10.1016/j.jcf.2014.09.014) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions